Table 2

Number and percentage of patients who cleared HBeAg at different times during the two therapeutic trials

TimeFirst trial treated cases (n=33)Second trial treated cases (n=74)First and second trial controls (n=59)
End of treatment6 (18%)2-150 10 (13%)** 2 (3%)
Six months after stopping treatment9 (27%)2-151 23 (31%)†† 5 (8%)
12 months after stopping treatment9 (27%)2-152 25 (34%)‡‡ 8 (13.5%)
  • 2-150 p<0.05,**p=0.06 v controls.

  • 2-151 p<0.05, ††p<0.01 v controls.

  • 2-152 p=ns, ‡‡p<0.05 v controls.